Ferulic acid / RadioS Cancer Research Results

FA, Ferulic acid: Click to Expand ⟱
Features:
Ferulic acid is an antioxidant found in some skin creams and serums.
Foods: popcorn, bamboo, whole-grain rye bread, whole-grain oat flakes, sweet corn (cooked)
Ferulic acid (FA) is a hydroxycinnamic acid abundant in plant cell walls (notably cereals/whole grains) with strong antioxidant and cytoprotective activity. Mechanistically, FA is frequently described as inducing Nrf2/HO-1 antioxidant programs and suppressing NF-κB-linked inflammation, with additional model-dependent anticancer effects (cell-cycle arrest, apoptosis, reduced invasion). Oral exposure is variable because FA is rapidly metabolized (often as conjugates) and bioaccessibility depends on the food matrix.

-Ferulic acid found in dietary strand fractions, especially its free form, has important functions for protecting the human health.
-AChE inhibitor (AD)
-Cooking results in an increase in free ferulic acid quantity and in a reduction in bound ferulic acid quantity.
Bamboo shoots       243.6 mg/100g
Sugar-beet pulp     800 mg/100g
Popcorn             313 mg/100g
Wheat bran	    500–1500mg/100g
Whole wheat flour   100–300mg/100g
            
Type of corn p-coumaric acidferulic acid
   mg/kg, DW mg/kg, DW
Yellow dent 18.9 265
American blue N.D. 927
Mexican blue 1.3 202
white 6.6 2484
Pathway / Target	Modulation by FA / Direction
Aβ aggregation	         ↓ Inhibits fibril formation and destabilizes existing Aβ fibrils 
BACE‑1 & APP	         ↓ Reduces BACE-1 and APP expression; ↑ MMP‑2/‑9 expression promoting Aβ clearance
Tau hyperphosphorylation  Implicitly ↓ through modulation of Ca²⁺/CDK5/GSK3β pathways
Ca²⁺         	         ↓ FA lowers STEP levels via chelation of Ca²⁺, suppressing PP2B → restores synaptic plasticity
(AChE / BChE)	         ↓ Inhibition of AChE (FA IC₅₀~15 µM, derivatives IC₅₀ down to 0.006 µM); also BChE
(MAO‑A/B)	         ↓ Inhibits MAO‑B (derivatives IC₅₀ ~0.3–0.7 µM), reducing ROS
ROS                      ↓ Scavenges ROS, enhances antioxidant enzymes (e.g., catalase), ↓ MDA
(COX‑2, 5‑LOX, NLRP3)	 ↓ Derivatives inhibit COX‑2/5‑LOX; derivative 13a ↓ NLRP3 inflammasome
Iron/Cu²⁺ chelation	 ↓ Metal-induced Aβ aggregation via chelation by FA and derivatives
Autophagy & Aβ clearance  ↗ Suggested promotion of autophagy mechanisms targeting Aβ
Rank Pathway / Axis Cancer Cells Normal Cells TSF Primary Effect Notes / Interpretation
1 Nrf2 → HO-1 / ARE antioxidant response Stress adaptation modulation (context-dependent) Nrf2 ↑; HO-1 ↑; antioxidant defenses ↑ R, G Endogenous antioxidant upshift FA is repeatedly reported to promote Nrf2 nuclear translocation and HO-1 induction; this is one of the most defensible “core” mechanisms.
2 NF-κB inflammatory transcription (COX-2 / iNOS / cytokines) NF-κB ↓; COX-2/iNOS and pro-inflammatory cytokine programs ↓ (reported) Inflammation tone ↓ (tissue protective) R, G Anti-inflammatory signaling Often described as downstream of redox changes and upstream of reduced inflammatory mediators; direction is consistent across many inflammation models.
3 ROS / oxidative stress tone Oxidative stress ↓ (often); ROS direction can vary by tumor model Oxidative injury ↓ P, R, G Redox buffering (context-dependent) FA is classically antioxidant; in tumor systems, effects may be secondary to signaling changes and vary with baseline redox instability.
4 Cell-cycle control (Cyclin D1 / CDK4/6; checkpoints) Cell-cycle arrest ↑ (reported); Cyclin D1 ↓; proliferation ↓ ↔ G Cytostasis Frequently reported as later phenotype-level outcomes; direction and checkpoint phase (G1 vs G2/M) vary by model.
5 Apoptosis (intrinsic caspase-linked; p53 axis in some models) Apoptosis ↑; caspase activation ↑ (reported); p53/p21 ↑ (model-dependent) ↔ (generally less activation) G Cell death execution Apoptosis is commonly observed in cancer models but is not as “signature-direct” as for mitochondrial toxins; best treated as downstream/conditional.
6 MAPK re-wiring (ERK / JNK / p38) MAPK modulation (context-dependent) ↔ P, R, G Signal reprogramming MAPK direction depends on whether FA is acting primarily as anti-inflammatory/anti-stress vs antiproliferative; avoid hard arrows for p38/JNK/ERK unless model-specific.
7 PI3K → AKT (± mTOR) survival axis PI3K/AKT modulation (reported; model-dependent) ↔ R, G Survival/growth modulation Often listed in anticancer summaries; treat as “reported” rather than universal primary mechanism.
8 Invasion / metastasis programs (MMPs / migration) MMPs ↓; migration/invasion ↓ (reported) ↔ G Anti-invasive phenotype Observed as later outcomes (gene expression + phenotype assays) and commonly linked to NF-κB/MAPK context.
9 Radiation/chemo injury mitigation (supportive care framing) Adjunct potential: may reduce treatment-associated oxidative/inflammatory injury (context) Tissue protection ↑ (reported) G Cytoprotection Animal models report radioprotective/anti-inflammatory effects; present as supportive/adjunct rather than standalone anticancer therapy.
10 Bioavailability / metabolism constraint (conjugation; food-matrix dependence) Systemic exposure variable; much appears as glucuronide/sulfate conjugates — — Translation constraint FA is absorbed and rapidly metabolized; “bioavailability” varies widely with food matrix and binding to polysaccharides in grains.

Time-Scale Flag (TSF): P / R / G

  • P: 0–30 min (primary/rapid effects; early redox interactions / rapid signaling shifts)
  • R: 30 min–3 hr (acute stress-response + transcription signaling shifts)
  • G: >3 hr (gene-regulatory adaptation and phenotype-level outcomes)
RadioS, RadioSensitizer: Click to Expand ⟱
Source:
Type:
A radiosensitizer is an agent that makes cancer cells more sensitive to the damaging effects of radiation therapy. By using a radiosensitizer, clinicians aim to enhance the effectiveness of radiation treatment by either increasing the damage incurred by tumor cells or by interfering with the cancer cells’ repair mechanisms. This can potentially allow for lower doses of radiation, reduced side effects, or improved treatment outcomes.
Pathways that help Radiosensitivity: downregulating HIF-1α, increase SIRT1, Txr

List of Natural Products with radiosensitizing properties:
-Curcumin:modulate NF-κB, STAT3 and has been shown in preclinical studies to enhance the effects of radiation by inhibiting cell survival pathways.
-Resveratrol:
-EGCG:
-Quercetin:
-Genistein:
-Parthenolide:

How radiosensitizers inhibit the thioredoxin (Trx) system in cellular contexts. Notable radiosensitizers, including:
-gold nanoparticles (GNPs),
-gold triethylphosphine cyanide ([Au(SCN) (PEt3)]),
-auranofin, ceria nanoparticles (CONPs),
-curcumin and its derivatives,
-piperlongamide,
-indolequinone derivatives,
-micheliolide,
-motexafin gadolinium, and
-ethane selenide selenidazole derivatives (SeDs)
Scientific Papers found: Click to Expand⟱
1656- FA,    Ferulic Acid: A Natural Phenol That Inhibits Neoplastic Events through Modulation of Oncogenic Signaling
- Review, Var, NA
tyrosinase↓, CK2↓, TumCP↓, TumCMig↓, FGF↓, FGFR1↓, PI3K↓, Akt↓, VEGF↓, FGFR1↓, FGFR2↓, PDGF↓, ALAT↓, AST↓, TumCCA↑, CDK2↓, CDK4↓, CDK6↓, BAX↓, Bcl-2↓, MMP2↓, MMP9↓, P53↑, PARP↑, PUMA↑, NOXA↑, Casp3↑, Casp9↑, TIMP1↑, lipid-P↑, mtDam↑, EMT↓, Vim↓, E-cadherin↓, p‑STAT3↓, COX2↓, CDC25↓, RadioS↑, ROS↑, DNAdam↑, γH2AX↑, PTEN↑, LC3II↓, Beclin-1↓, SOD↓, Catalase↓, GPx↓, Fas↑, *BioAv↓, cMyc↓, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↓,
1654- FA,    Molecular mechanism of ferulic acid and its derivatives in tumor progression
- Review, Var, NA
AntiCan↑, Inflam↓, RadioS↑, ROS↑, Apoptosis↑, TumCCA↑, TumCMig↑, TumCI↓, angioG↓, ChemoSen↑, ChemoSideEff↓, P53↑, cycD1/CCND1↓, CDK4↓, CDK6↓, TumW↓, miR-34a↑, Bcl-2↓, Casp3↑, BAX↑, β-catenin/ZEB1↓, cMyc↓, Bax:Bcl2↑, SOD↓, GSH↓, LDH↓, ERK↑, eff↑, JAK2↓, STAT6↓, NF-kB↓, PYCR1↓, PI3K↓, Akt↓, mTOR↓, Ki-67↓, VEGF↓, FGFR1↓, EMT↓, CAIX↓, LC3II↑, p62↑, PKM2↓, Glycolysis↓, *BioAv↓,

Showing Research Papers: 1 to 2 of 2

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 2

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

Catalase↓, 1,   GPx↓, 1,   GSH↓, 1,   lipid-P↑, 1,   PYCR1↓, 1,   ROS↑, 2,   SOD↓, 2,  

Mitochondria & Bioenergetics ⓘ

CDC25↓, 1,   FGFR1↓, 3,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   CAIX↓, 1,   cMyc↓, 2,   Glycolysis↓, 1,   LDH↓, 1,   PKM2↓, 1,  

Cell Death ⓘ

Akt↓, 2,   Apoptosis↑, 1,   BAX↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Casp3↑, 2,   Casp9↑, 1,   CK2↓, 1,   Fas↑, 1,   NOXA↑, 1,   PUMA↑, 1,  

Autophagy & Lysosomes ⓘ

Beclin-1↓, 1,   Beclin-1↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↓, 1,   LC3II↓, 1,   LC3II↑, 1,   p62↑, 1,  

DNA Damage & Repair ⓘ

DNAdam↑, 1,   P53↑, 2,   PARP↑, 1,   γH2AX↑, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 2,   cycD1/CCND1↓, 1,   TumCCA↑, 2,  

Proliferation, Differentiation & Cell State ⓘ

EMT↓, 2,   ERK↑, 1,   FGF↓, 1,   FGFR2↓, 1,   miR-34a↑, 1,   mTOR↓, 1,   PI3K↓, 2,   PTEN↑, 1,   p‑STAT3↓, 1,   STAT6↓, 1,   tyrosinase↓, 1,  

Migration ⓘ

E-cadherin↓, 1,   Ki-67↓, 1,   MMP2↓, 1,   MMP9↓, 1,   PDGF↓, 1,   TIMP1↑, 1,   TumCI↓, 1,   TumCMig↓, 1,   TumCMig↑, 1,   TumCP↓, 1,   Vim↓, 1,   β-catenin/ZEB1↓, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 1,   VEGF↓, 2,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 1,   Inflam↓, 1,   JAK2↓, 1,   NF-kB↓, 1,  

Hormonal & Nuclear Receptors ⓘ

CDK6↓, 2,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,   eff↑, 1,   RadioS↑, 2,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   AST↓, 1,   Ki-67↓, 1,   LDH↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   ChemoSideEff↓, 1,   TumW↓, 1,  
Total Targets: 82

Pathway results for Effect on Normal Cells:


Drug Metabolism & Resistance ⓘ

BioAv↓, 2,  
Total Targets: 1

Scientific Paper Hit Count for: RadioS, RadioSensitizer
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:77  Target#:1107  State#:%  Dir#:2
  wNotes=0  sortOrder:rid,rpid

 

Home Page